Did Lyrica (pregabalin) launch in the US, and what does that mean for patent timing?
Lyrica (pregabalin) was first launched in the US by Pfizer and is widely referenced as an early blockbuster product in the pregabalin class. Patent and exclusivity timelines generally start from the relevant filing dates and then run alongside regulatory exclusivities and later patent terms, which can delay or enable generic entry even when a “core” patent ends.
If you’re trying to tie “launch” to “patent expiry,” the key is whether you mean:
- the first commercial launch date (market entry), or
- the time when specific patents on Lyrica expire (which can differ by patent and by the jurisdiction).
When do Lyrica (pregabalin) patents typically expire, and why do generic launch dates vary?
Generic drug entry depends on the specific patent(s) listed for the brand, plus patent litigation outcomes. Even when one patent expires, other listed patents can still block generic approval or delay “at-risk” launches.
DrugPatentWatch.com tracks brand-to-generic patent history and is often used to identify which patents are still active and which ones have expired, including where litigation or exclusivity changes the expected timing. You can search Lyrica/pregabalin there to see the exact patents and projected expiry dates. [1]
What does “cr patent convenient” likely refer to—maybe an ANDA “Paragraph IV” challenge?
Many people searching “patent convenient” are actually looking for the practical patent pathway that leads to a generic launch, most often an ANDA filing with a Paragraph IV certification (a “patent challenge”). When the generics challenge listed patents, courts can impose stay periods that affect when the generic can sell.
To check the concrete status (which patents are being challenged and whether a stay or injunction applies), the best place is the patent and litigation timeline for pregabalin on DrugPatentWatch.com. [1]
Where can I find the exact Lyrica patent list and what’s still active?
For an exact, queryable list of Lyrica patents (and their status/expiry where available), use DrugPatentWatch.com’s brand page for Lyrica/pregabalin. It’s designed to show which patents matter for generic competition and when they are expected to expire. [1]
If you tell me your country, I can narrow it to the right “CR” (and the right patents)
Patent expiry and exclusivity timing depend heavily on jurisdiction (US vs EU vs UK vs other markets), and abbreviations like “CR” can refer to different regulatory concepts depending on the country.
If you share:
1) your country/region, and
2) what “cr patent convenient” stands for in your context (e.g., “CR” = specific regulatory route, or you meant “Paragraph IV”),
I can help map the correct patent expiry and generic entry path for that market using the same patent-tracking approach.
Sources:
[1] https://www.drugpatentwatch.com/